证券代码：002773 证券简称：康弘药业 公告编号：2025-016 成都康弘药业集团股份有限公司 关于注销2021年股票期权激励计划部分股票期权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第八届董事会第十次会议，审议通过了《关于注销 2021 年股票期权激励计划部分股票期权的议案》。现将有关事项说明如下： 一、 2021 年股票期权激励计划简述及已履行的程序 1、2021 年 6 月 18 日，公司召开第七届董事会第十次会议，审 议通过了《关于公司<2021 年股票期权激励计划（草案）>及其摘要的 议案》《关于公司<2021 年股票期权激励计划考核实施管理办法>的议 案》和《关于提请股东大会授权董事会及其授权人士全权办理 2021 年股票期权激励计划相关事宜的议案》。公司独立董事对该事项发表 了同意的独立意见。 2、2021 年 6 月 18 日，公司召开第七届监事会第七次会议，审 议通过了《关于公司<2021 年股票期权激励计划（草案）>及其摘要的 议案》《 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥1,198,743,422.58, representing a 9.70% increase compared to ¥1,092,784,087.91 in the same period last year[5] - Net profit attributable to shareholders was ¥400,017,678.69, up 7.09% from ¥373,521,473.06 year-on-year[5] - The basic earnings per share for Q1 2025 was ¥0.43, a 4.88% increase from ¥0.41 in the same period last year[5] - Total operating revenue for the current period reached ¥1,198,743,422.58, an increase of 9.7% compared to ¥1,092,784,087.91 in the previous period[21] - Net profit for the current period was ¥396,624,766.47, representing a 6.8% increase from ¥371,475,098.05 in the previous period[22] - Total comprehensive income amounted to CNY 396,106,074.20, an increase from CNY 370,888,415.97 in the previous period, representing a growth of approximately 6.5%[23] - The company’s total comprehensive income attributable to the parent company was CNY 399,498,986.42, up from CNY 372,934,790.98, representing an increase of approximately 7.1%[23] Cash Flow and Liquidity - The net cash flow from operating activities increased by 6.69% to ¥433,077,896.44, compared to ¥405,935,869.60 in the previous year[5] - The company's cash and cash equivalents increased, contributing to a stronger liquidity position[19] - Cash inflow from sales of goods and services reached CNY 1,208,720,347.20, up from CNY 1,158,201,461.54, marking a growth of approximately 4.3%[25] - The ending balance of cash and cash equivalents was CNY 3,369,779,954.96, an increase from CNY 3,072,565,305.73 in the previous period[26] - The company reported a net increase in cash and cash equivalents of CNY -2,255,647,291.60, compared to CNY -1,597,428,914.87 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥9,672,737,904.71, reflecting a 3.54% increase from ¥9,341,936,339.67 at the end of the previous year[5] - Total liabilities decreased to ¥627,524,264.95 from ¥695,069,259.77, a reduction of 9.7%[19] - The equity attributable to shareholders of the parent company rose to ¥9,054,671,602.23, compared to ¥8,653,202,130.15, an increase of 4.6%[19] Research and Development - Research and development expenses rose by 47.70% to ¥94,301,139.91, compared to ¥63,845,609.61 in the same period last year, indicating increased investment in R&D[11] - Research and development expenses for the current period were ¥94,301,139.91, up from ¥63,845,609.61, indicating a significant increase of 47.8%[22] - The company has received clinical trial approval for KHN702 from the National Medical Products Administration, indicating progress in its drug development pipeline[15] - The company’s subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received approval for the Phase I clinical trial of KH815 from the Australian Human Research Ethics Committee, showcasing its international research capabilities[15] Shareholder Information - The top shareholder, Chengdu Kanghong Technology Industry Group Co., Ltd., holds a 31.75% stake, indicating strong insider ownership[14] - The second-largest shareholder, Ke Zunhong, owns 22.58% of the shares, further emphasizing significant insider control[14] - The company has a diverse shareholder base, with the top ten shareholders holding a combined total of 80.56% of the shares, indicating concentrated ownership[14] - The company has not reported any changes in the participation of major shareholders in margin trading activities[15] - The company has not disclosed any other significant matters that could impact its financial performance or strategic direction[15] Revenue Breakdown - The revenue from traditional Chinese medicine products was ¥38,411.55 million, showing a 9.71% increase compared to ¥35,012.49 million last year[6] - The revenue from biological drugs increased by 18.56% to ¥64,349.84 million, up from ¥54,274.38 million in the previous year[6] - The company reported a significant increase of 723.00% in other business revenue, reaching ¥102.71 million compared to ¥12.48 million last year[6] Investment Activities - The company holds trading financial assets valued at ¥2,640,000,000.00, indicating a strategic investment in financial instruments[17] - The company reported a net investment loss of ¥134,361.58, compared to a loss of ¥53,158.67 in the previous period[22] - Total cash outflow from investing activities was CNY 2,687,500,476.51, compared to CNY 2,003,173,073.60 in the previous period, reflecting an increase of about 34.2%[26] - The net cash flow from investing activities was negative at CNY -2,687,151,662.15, worsening from CNY -2,003,006,385.60 in the previous period[26]

Financial Performance - The company's operating revenue for 2024 reached ¥4,452,657,799, representing a 12.51% increase compared to ¥3,957,459,641.68 in 2023[6]. - Net profit attributable to shareholders for 2024 was ¥1,191,230,760.93, up 14.02% from ¥1,044,765,761.76 in 2023[6]. - The cash flow from operating activities for 2024 was ¥1,411,874,837.73, reflecting a 15.88% increase from ¥1,218,411,128.75 in 2023[6]. - Basic earnings per share for 2024 were ¥1.3, a 14.04% increase from ¥1.14 in 2023[6]. - Total assets at the end of 2024 amounted to ¥9,341,936,339.67, a 9.52% increase from ¥8,529,680,910.70 at the end of 2023[6]. - The total revenue for 2024 reached ¥4,452,657,799, representing a year-on-year increase of 12.51% compared to ¥3,957,459,641.6 in 2023[57]. - The pharmaceutical manufacturing segment contributed ¥4,451,169,730.5, accounting for 99.97% of total revenue, with a year-on-year growth of 12.49%[57]. - The biopharmaceutical product line saw significant growth, generating ¥2,342,687,346.2, which is a 20.98% increase from ¥1,936,471,767.2 in the previous year[57]. - The company achieved a revenue of 445,265.78 million yuan, representing a year-on-year growth of 12.51%[51]. - The net profit attributable to shareholders was 119,123.08 million yuan, with a year-on-year increase of 14.02%[51]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares to all shareholders, based on a total of 919,869,004 shares[3]. - The company distributed a cash dividend of 3.80 RMB per 10 shares, totaling 551,921,402.40 RMB, which represents 100% of the total profit distribution[145][146]. - The board of directors approved a dividend payout of 0.5 RMB per share, reflecting a commitment to returning value to shareholders[127]. Research and Development - The company has completed a product layout focusing on chronic disease prevention and treatment, particularly in hypertension and diabetes[28]. - The company plans to increase investment and research in fields such as ophthalmology, psychiatry/neuroscience, and oncology[28]. - The company focuses on research, manufacturing, and sales of pharmaceutical products and medical devices, maintaining a commitment to innovation and collaboration[33]. - The company has developed key technologies in biopharmaceutical industrialization, synthetic biology, and standardized quality control for traditional Chinese medicine[33]. - The company is developing multiple new drugs, including KH110 for Alzheimer's disease and KH109 for anxiety, both currently in Phase III clinical trials[44]. - The company has ongoing clinical trials for key projects, including KH631 for wet age-related macular degeneration and KH617 for advanced solid tumors[43]. - The company has established a comprehensive R&D system, integrating domestic and international resources for product innovation and technology enhancement[43]. - The company is currently conducting multiple Phase I clinical trials for innovative gene therapies targeting age-related macular degeneration, which are expected to enhance its competitive edge in ophthalmic treatments[67]. - The company is expanding its product pipeline with new indications for existing drugs, enhancing its market position in mental health treatments[68]. - R&D investment rose by 33.57% to approximately ¥604.38 million in 2024, accounting for 13.57% of operating revenue[68]. Market and Competitive Landscape - The innovative drug market in China has exceeded 700 billion RMB in 2023, with expectations to reach 800 billion RMB by 2029, indicating a strong growth trajectory[32]. - The aging population in China presents significant opportunities for the company to address chronic disease treatment, enhancing its market potential[32]. - The competitive landscape in the domestic pharmaceutical market is intensifying, necessitating continuous innovation from local companies to enhance market competitiveness[30]. - The company is actively expanding its international market presence and has secured patents for several first-class new drugs[46]. - The company is focused on expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[122]. Environmental Compliance and Sustainability - The company adheres to numerous environmental protection laws and standards during its operations, ensuring compliance with regulations[162]. - The company has received various environmental approvals for projects, including the solid oral dosage technology transformation and the innovation biological new drug laboratory[163]. - The company has established a comprehensive internal control system to prevent fraud and ensure accurate financial reporting[158]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating its commitment to environmental responsibility[162]. - The company has implemented stringent monitoring protocols for emissions, ensuring that all measured values remain compliant with environmental regulations[171]. - The company continues to monitor and ensure that all emissions remain within regulatory standards, reflecting its commitment to sustainability[176]. - The company has achieved zero occupational disease accidents in 2024, with full coverage of occupational health check-ups and health records for employees[199]. - The company has not experienced any major product quality responsibility accidents in 2024 and has not received confirmed complaints regarding customer privacy violations[200]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholders[108]. - The company is committed to enhancing its value management system and has disclosed plans for valuation improvement[105]. - The company has a structured approach to performance-based incentives for its senior management team[128]. - The company held its annual shareholder meeting on May 16, 2024, with a participation rate of 71.82%[109]. - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including the current chairman who has over 40 years of experience[114]. - The company is focused on maintaining a stable management structure despite the upcoming resignations, ensuring continuity in leadership[112][113]. Employee and Talent Management - The company has established a unique human resource management model to attract and develop talent in R&D, production, and sales[45]. - The number of R&D personnel increased by 4.75% from 569 in 2023 to 596 in 2024[68]. - The company has implemented a comprehensive training program for employees, utilizing various training methods and platforms[143]. - The total number of employees at the end of the reporting period was 4,462[141]. - The company has 406 employees with a master's degree or above, and 1,995 employees with a bachelor's degree[141]. Future Outlook and Strategic Initiatives - The company plans to expand its market presence significantly by 2026, targeting a revenue increase to 264.4 million[111]. - The company aims to enhance its product offerings and technological advancements by 2026, with a focus on innovative drug development[115]. - Future investments will focus on innovative drug development in high-incidence diseases and chronic conditions, leveraging cutting-edge technologies like gene therapy and antibody development[96]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness by 40% in the next six months[126]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product portfolio[115].

康弘药业（002773）公告，公司全资子公司北京康弘生物医药有限公司拟吸收合并北京弘健医疗器械有 限公司、四川康弘中药材种植有限公司拟吸收合并成都康弘医药贸易有限公司、四川济生堂药业有限公 司拟吸收合并四川济生堂兴尚生物科技有限责任公司。吸收合并后，北京康弘生物、康弘种植、济生堂 存续经营，公司名称、股权结构保持不变。北京弘健、成都康贸、兴尚生物依法注销，其全部资产、负 债、业务、人员、相关资质及其他一切权利义务均由北京康弘生物、康弘种植、济生堂分别依法承继。 ...

康弘药业（002773）公告，2025年第一季度营业收入11.99亿元，同比增长9.70%。净利润4亿元，同比 增长7.09%。 ...

成都康弘药业集团股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 页码 | | --- | | 专项说明 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | t and the state | 信永中和会计师事务所 北京市东城区朝阳门北大街 联系电话: +86(010)6554 2288 | | | | --- | --- | --- | | telephone: +86 (010) 6554 2288 | 8 号富华大厦 A 座 9 层 | | | ShineWing | 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidajie, | +86 (010) 6554 7190 | | Dongcheng District, Beijing, 传真: | | | | certified public accountants 100027, P.R. China | | facsimile: +86 (010) 6554 7190 | 关于成都康弘药业集团股份有限公司 2024 年度非经营性资金占用及其他关 ...

中银国际证券股份有限公司关于 成都康弘药业集团股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中银国际证券股份有限公司（以下简称"保荐机构"）作为成都康弘药业集 团股份有限公司（以下简称"康弘药业"、"公司"）持续督导的保荐机构，根据《中 华人民共和国公司法》、《证券发行上市保荐业务管理办法》、《深圳证券交易所股 票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》、《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》及 《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》等相关 法律、法规及规范性文件的规定，对康弘药业 2024 年度募集资金使用情况进行 了核查，发表核查情况如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 1、2015 年首次公开发行股票 经中国证券监督管理委员会"证监许可[2015]1198 号文"核准，成都康弘药业 集团股份有限公司公开发行人民币普通股股票 4,560.00 万股，每股发行价为 13.62 元，扣除证券公司承销费、保荐费等费用后实际募集资金净额为人民币 57,624.77 万元。上述募 ...

北京通商（成都）律师事务所 关于 成都康弘药业集团股份有限公司 2021 年股票期权激励计划 注销部分股票期权的 法律意见书 二〇二五年四月 通 商津 師事務所 COMMERCE & FINANCE LAW OFFICES 通 商津 師事務所 Commerce & Finance Law Offices 目录 | 一、本次注销事项的批准与授权… | | --- | | 二、本激励计划注销部分股票期权的具体情况 | | 三、结论意见 | 2 通 商津 師事務所 COMMERCE & FINANCE LAW OFFICES 释义 在本法律意见书中,除非文中另有说明,下列词语具有如下涵义: | 本所 | 指 | 北京通商(成都)律师事务所 | | --- | --- | --- | | 公司或康弘药业 | 指 | 成都康弘药业集团股份有限公司 | | 本激励计划 | 指 | 成都康弘药业集团股份有限公司 2021 年股票期权激励计划 | | 《激励计划(草案)》 | 指 | 《成都康弘药业集团股份有限公司 2021年股票期权激励计划 | | | | (草案)》 | | 股票期权 | 指 | 公司授予激励对象在未来一 ...

北京市东城区朝阳门北大街 计师事务所 8 号宫华大厦 A 座 ( 成都康弘药业集团股份有限公司 2024 年 12 月 31 日 内部控制审计报告 索引 内部控制审计报告 页码 1-2 联系申话· 内部控制审计报告 XYZH/2025CDAA5B0126 成都康弘药业集团股份有限公司 成都康弘药业集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计 了成都康弘药业集团股份有限公司(以下简称康弘药业公司)2024年12月31日财务报 告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》 、《企业内部控制应用指引》 、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是康弘药业公司董事 会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意 见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的 变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内 ...

成都康弘药业集团股份有限公司 2024 年度 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-4 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-90 | 3条所 北京市东城区朝阳门北大街 群系申话 telenhone: 8 号富华大厦 A 座 9 层 +86 (010) 6554 2288 Donachana District R 审计报告 XYZH/2025CDAA5B0127 成都康弘药业集团股份有限公司 成都康弘药业集团股份有限公司全体股东: 一、审计意见 我们审计了成都康弘药业集团股份有限公司(以下简称康弘药业公司)财务报表, 包括 2024年 12月 31日的合并及母公司资产负债表,2024年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司股东权益变动表,以 ...